In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Serious Bleeding Side Effects
Xarelto® is the name under which Janssen Pharmaceuticals, Inc. markets a prescription anticoagulant medication generically called rivaroxaban.
Xarelto is a blood-thinning drug used to reduce the risk of ischemic stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem as well as treatments for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Since coming on the market in 2011 the FDA has received numerous Adverse Event Reports involving the following Xarelto bleeding side effects:
- Serious bleeding side effects such as gastrointestinal (GI) bleeds and rectal bleeding
- Irreversible life-threatening bleeding events
- Trauma-induced atypical bleeding incidents due to lack of effective reversal agent
- Hemorrhages such as brain hemorrhage, intracranial hemorrhage, and hemorrhagic stroke
- Death as a result of excessive bleeding
Symptoms of these major bleeding complications include:
Coughing up blood
We point out that these two important facts about these bleeding events:
- Xarelto is associated with an increase in the rate of major gastrointestinal (GI) bleeding despite the lower rates of bleeding at other sites; and,
- A trend of higher bleeding risk was seen with advancing age.
Other Xarelto Side Effects
In addition, some medical studies have associated Xarelto with an increased risk of these other various side effects:
- Drug-induced liver injury (DILI)
- Thromboembolic complications such as cerebrovascular accident (CVA)
- Heart attack
- Myocardial infarction (MI)
- Acute coronary syndrome (ACS)
- Cardiac bleeds
We are handling personal injury and wrongful death lawsuits involving these Xarelto-related bleeding events as well as the other serious side effects.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban).
Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation”.
Also earlier this month, JAMA Internal Medicine published this article, “Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.”
We get these insights from this October 7, 2016 article, “More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?”:
The two new studies [published in the medical journal Chest and JAMA Internal Medicine] come close on the heels of an analysis by Danish researchers comparing [Pradaxa (dabigatran)], [Xarelto (rivaroxaban)], [Eliquis (apixaban)], and warfarin. In that analysis, [Pradaxa (dabigatran)] and [Eliquis (apixaban)] were associated with a significantly decreased risk of ICH compared with warfarin, but [Xarelto (rivaroxaban)] was not, although all three [non-vitamin K antagonist oral anticoagulants (NOACs)] were as effective as warfarin at reducing stroke in atrial fibrillation patients….
To date there are no randomized head-to-head trials comparing the new agents, but that is about to change. [Laila Stærk, MD (Herlev and Gentofte University Hospital, Denmark), who presented that data at the recent European Society of Cardiology Congress 2016,] told TCTMD that a new prospective, cluster randomized trial has just been announced in Denmark that will involve “almost all” hospitals in the country. Designed to run for 4 years, each hospital will just use one of the four approved NOACs ([Pradaxa (dabigatran)], [Xarelto (rivaroxaban)], [Savaysa (edoxaban)], and [Eliquis (apixaban)]) for the period of 1 year, then the next the next year, and so forth. At the end of the 4-year period, every participating hospital will have 1 year’s experience with each of the approved NOACs, with follow-up to continue for several years thereafter. Dubbed DEN-NOAC, the trial will be led by Casper Bang, MD (Rigshospitalet, Copenhagen, Denmark).
Of course, we will continue to monitor the still-emerging safety issues surrounding Eliquis, Savaysa, and Xarelto.
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
- Eliquis, Savaysa, And Xarelto Worry Doctors Because No Antidote, Still
- Eliquis Might Be Safer Than Xarelto, But Neither Has Approved Antidote
- Xarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
- No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
- Xarelto – Liver Side Effects: Will New Warning Be Added To Drug Label?
- Xarelto: Drug-Induced Liver Injury Warning Should Be Added To Drug Label Prescribing Information For Xarelto Say Medical Researchers
- Eliquis And Xarelto, Like Pradaxa, Linked To Serious Bleeding Events Due To Fact No Antidote Available
- Drug Safety Significance Of Adverse Reactions Reports For Xarelto Blood Thinner Pill Is Uncertain, At Best
All content by attorney Tom Lamb